LY3549492 for Obesity

Recruiting at 53 trial locations

Overseen ByJeffrey A Norton

Age: 18+

Sex: Any

Trial Phase: Phase 2

Sponsor: Eli Lilly and Company

Disqualifiers: Diabetes, Pancreatitis, Renal impairment, others

Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The main purpose of this study, performed under the master protocol W8M-MC-CWMM (NCT06143956), is to evaluate the effects of LY3549492 in adults with obesity or overweight. Participation in the study will last about one year.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

Who Is on the Research Team?

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Are You a Good Fit for This Trial?

This clinical trial is for adults who are overweight or have obesity. Participants will be involved in the study for about one year to assess the effectiveness of a new medication, LY3549492.

Inclusion Criteria

I was assigned male at birth.

W8M-MC-CWMM: Have a BMI ≥27 kilograms per square meter (kg/m²)

My weight has been stable, with less than 5% change, for the last 3 months.

See 1 more

Exclusion Criteria

W8M-MC-GN01: Individuals who are of childbearing potential

I have had symptoms of gallbladder disease in the last 2 years.

W8M-MC-CWMM: Have a lifetime history of suicide attempts

See 8 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive LY3549492 or placebo orally for weight management

48 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

LY3549492

Trial Overview The trial is testing LY3549492 against a placebo to see if it helps with weight management. A placebo is an inactive substance that looks like the drug but has no treatment value.

How Is the Trial Designed?

6Treatment groups

Experimental Treatment

Placebo Group

Group I: LY3549492 Dose 5Experimental Treatment1 Intervention